Ibandronate (Boniva)
Revision as of 01:05, 29 June 2024 by Warner-admin (talk | contribs) (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.[1][2][3][4][5]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Patient counseling information can be found on page 17-21 of the Ibandronate (Boniva) package insert[1]
- Patient counseling information can be found on page 18-21 of the Ibandronate injection (Boniva injection) package insert[3]
- Ibandronate (Boniva) patient drug information (UpToDate)[6]
Also known as
- Generic names: ibandronate sodium, ibandronic acid
- Brand names: Bandrobon, Bandrone, Bondenza, Bondronat, Boniva, Bonviva, Femorel
References
- ↑ 1.0 1.1 1.2 Ibandronate (Boniva) package insert
- ↑ Ibandronate (Boniva) package insert (locally hosted backup)
- ↑ 3.0 3.1 Ibandronate injection (Boniva injection) package insert
- ↑ Ibandronate injection (Boniva injection) package insert (locally hosted backup)
- ↑ Boniva manufacturer's website
- ↑ Ibandronate (Boniva) patient drug information (UpToDate)